KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) EPS (Weighted Average and Diluted): 2010-2025

Historic EPS (Weighted Average and Diluted) for Novavax (NVAX) over the last 6 years, with Sep 2025 value amounting to -$1.25.

  • Novavax's EPS (Weighted Average and Diluted) fell 64.47% to -$1.25 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.78, marking a year-over-year increase of 177.73%. This contributed to the annual value of -$1.23 for FY2024, which is 77.26% up from last year.
  • As of Q3 2025, Novavax's EPS (Weighted Average and Diluted) stood at -$1.25, which was down 301.61% from $0.62 recorded in Q2 2025.
  • In the past 5 years, Novavax's EPS (Weighted Average and Diluted) ranged from a high of $2.93 in Q1 2025 and a low of -$11.31 during Q4 2021.
  • In the last 3 years, Novavax's EPS (Weighted Average and Diluted) had a median value of -$0.76 in 2024 and averaged -$0.42.
  • As far as peak fluctuations go, Novavax's EPS (Weighted Average and Diluted) tumbled by 779.63% in 2021, and later spiked by 379.05% in 2025.
  • Novavax's EPS (Weighted Average and Diluted) (Quarterly) stood at -$11.31 in 2021, then spiked by 79.75% to -$2.29 in 2022, then spiked by 35.81% to -$1.47 in 2023, then soared by 64.63% to -$0.52 in 2024, then crashed by 64.47% to -$1.25 in 2025.
  • Its EPS (Weighted Average and Diluted) was -$1.25 in Q3 2025, compared to $0.62 in Q2 2025 and $2.93 in Q1 2025.